Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 4.04%98.6B | 7.11%394.31B | 7.46%98.84B | 7.57%104.65B | 6.83%96.04B | 6.53%94.78B | 2.75%368.13B | 3.41%91.98B | 0.05%97.28B | 4.94%89.9B |
Cost of revenue | 1.98%65.88B | 8.81%273.89B | 9.07%71.93B | 9.11%69.59B | 7.73%67.78B | 9.35%64.6B | 3.39%251.71B | 1.20%65.94B | -1.55%63.77B | 9.41%62.92B |
Gross profit | 8.44%32.73B | 3.44%120.42B | 3.37%26.92B | 4.65%35.07B | 4.73%28.26B | 0.97%30.18B | 1.39%116.42B | 9.48%26.04B | 3.23%33.51B | -4.18%26.98B |
Operating expense | 13.91%26.55B | 10.05%105.24B | 13.09%28.78B | 14.29%26.77B | 9.48%26.39B | 2.84%23.3B | 1.23%95.64B | -4.46%25.45B | -1.82%23.42B | 7.94%24.1B |
Operating profit | -10.11%6.18B | -26.98%15.18B | -416.64%-1.87B | -17.75%8.3B | -35.07%1.87B | -4.88%6.87B | 2.15%20.78B | 120.65%589M | 17.24%10.09B | -50.59%2.88B |
Net non-operating interest income (expenses) | 80.00%-1M | 74.60%-16M | 0 | 86.67%-2M | 50.00%-9M | 72.22%-5M | 18.18%-63M | 25.00%-12M | 21.05%-15M | 18.18%-18M |
Non-operating interest income | -25.00%3M | -13.33%13M | -57.14%3M | 33.33%4M | -33.33%2M | 100.00%4M | 7.14%15M | 16.67%7M | 0.00%3M | 50.00%3M |
Non-operating interest expense | -55.56%4M | -62.82%29M | -84.21%3M | -66.67%6M | -47.62%11M | -55.00%9M | -14.29%78M | -13.64%19M | -18.18%18M | -12.50%21M |
Net investment income | -12.49%6.09B | -16.78%12B | -25.45%328M | -39.18%4.31B | 2.01%407M | 7.08%6.96B | 33.51%14.42B | -20.58%440M | 23.71%7.09B | 15.65%399M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 88.32%8.24B | 73.53%34.85B | -97.67%469M | 3,404.91%30B | 0 | 671.76%4.37B | 9.13%20.08B | 13.87%20.12B | 1,158.82%856M | -131M |
Income from associates and other participating interests | -81.93%58M | 1,051.89%1.22B | 2,041.67%699M | 129.03%142M | 1,083.33%59M | 273.26%321M | -65.25%106M | 12.20%-36M | -77.12%62M | -103.87%-6M |
Special income (charges) | 155.56%1.88B | -259.69%-4.95B | 73.10%-301M | -172.90%-292M | -682.40%-978M | -12,907.69%-3.38B | 23.29%-1.38B | -246.44%-1.12B | 0.93%-107M | -1,488.89%-125M |
Less:Restructuring and mergern&acquisition | 194.12%150M | 64.68%1.08B | -85.09%82M | -36.11%46M | 2,706.25%898M | --51M | -45.04%654M | --550M | 414.29%72M | --32M |
Less:Other special charges | -160.91%-2.03B | 538.35%3.86B | -55.34%205M | 602.86%246M | -5.88%80M | 12,711.54%3.33B | 21.49%605M | 75.86%459M | -62.77%35M | 257.41%85M |
Less:Write off | ---- | -88.14%14M | -87.27%14M | --0 | ---- | ---- | 10.28%118M | 77.42%110M | --0 | ---- |
Other non-operating income (expenses) | 34.62%-51M | -1,680.00%-553M | -1,286.96%-273M | -110.26%-246M | -38.89%44M | -236.84%-78M | 119.13%35M | 110.45%23M | -800.00%-117M | 80.00%72M |
Income before tax | 48.68%22.39B | 6.92%57.72B | -104.71%-943M | 136.49%42.21B | -54.61%1.39B | 15.29%15.06B | 12.95%53.98B | 35.43%20.01B | 22.86%17.85B | -51.73%3.07B |
Income tax | 42.08%7.14B | 3.57%18.25B | -116.37%-978M | 146.37%13.41B | -27.16%794M | -1.76%5.03B | 16.29%17.63B | 36.96%5.97B | 17.33%5.44B | -45.20%1.09B |
Net income | 51.97%15.24B | 8.55%39.47B | -99.74%36M | 132.17%28.8B | -69.80%598M | 26.29%10.03B | 11.39%36.36B | 34.80%14.03B | 25.46%12.41B | -54.69%1.98B |
Net income continuous operations | 51.98%15.24B | 8.54%39.47B | -99.75%35M | 132.15%28.8B | -69.73%599M | 26.27%10.03B | 11.39%36.36B | 34.80%14.03B | 25.45%12.41B | -54.70%1.98B |
Noncontrolling interests | 175.80%866M | 13.86%1.34B | 1,426.67%229M | -27.15%314M | 24.55%482M | -8.45%314M | 86.37%1.18B | 106.47%15M | -16.47%431M | -24.56%387M |
Net income attributable to the company | 47.99%14.38B | 8.37%38.13B | -101.38%-193M | 137.89%28.49B | -92.65%117M | 27.85%9.72B | 9.92%35.18B | 31.72%14.02B | 27.77%11.98B | -58.71%1.59B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 47.99%14.38B | 8.37%38.13B | -101.38%-193M | 137.89%28.49B | -92.65%117M | 27.85%9.72B | 9.92%35.18B | 31.72%14.02B | 27.77%11.98B | -58.71%1.59B |
Gross dividend payment | ||||||||||
Basic earnings per share | 50.99%88.95 | 11.27%232.28 | -100.34%-0.28 | 143.61%172.94 | -92.54%0.71 | 31.44%58.91 | 11.43%208.76 | 33.98%83.43 | 29.43%70.99 | -57.80%9.52 |
Diluted earnings per share | 50.99%88.95 | 11.27%232.28 | -101.43%-1.1941 | 143.61%172.94 | -92.49%0.7084 | 31.44%58.91 | 11.43%208.76 | 33.98%83.43 | 29.43%70.99 | -58.19%9.432 |
Dividend per share | 0 | 4.76%44 | 0.00%22 | 0 | 10.00%22 | 0 | 13.51%42 | 0.00%22 | 0 | 33.33%20 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |